Atrial fibrillation research
Atrial fibrillation is the most common sustained cardiac arrhythmia. It can affect 1% of the population, with elderly people or those with heart disease being particularly at risk.
In most cases, it is caused by bursts of abnormal electrical discharges, which force the atria to activate very rapidly and irregularly.
Atrial fibrillation can begin as paroxysmal (with spontaneous terminations) and evolve to persistent when, in addition to the triggering foci, lesions, and alterations in the functioning of the atria coexist.
This disease is associated with heart failure, favors embolisms, and causes symptoms that greatly impair quality of life. The presence of atrial fibrillation can increase mortality because it causes heart failure and embolisms, but also because it increases the risk of sudden death.
We dream to prevent and cure atrial fibrilation
In recent years, progress has been made in treatments to mitigate the symptoms, but there is still a lack of therapeutic alternatives to slow the progression or improve the prognosis of this disease.
We delve into the pathophysiological mechanisms that cause the onset and development of the disease.
We seek to find new biomarkers for a better individualized stratification of patients and to validate new targets to improve their treatment.
We work closely with researchers and clinicians to rapidly translate discoveries from the laboratory to the patient.
REFERENCES IN TRANSLATIONAL RESEARCH
Heart Failure Research Group
Reference team in the clinical and preclinical research on atrial fibrillation associated with heart failure for an individualized diagnosis of this pathology, identifying the alterations underlying its onset and progression and developing more effective, precise and personalized therapeutic strategies.
It is part of the Cardiovascular Diseases Program.